Structural insights into a potent antimalarial drug candidate’s interaction with a malaria parasite have paved the way for drug-resistant malaria therapies, according to a new study by researchers at Weill Cornell Medicine and Van Andel Institute.
Non-cancerous cells called stromal cells, which are found in and around prostate tumors, may be useful in assessing these tumors’ potential to spread, and may even be targets for future prostate cancer treatments, according to a study led by researchers at Weill Cornell Medicine.
A multidisciplinary task force of Cornell faculty and staff has issued a report offering perspectives and practical guidelines for the use of generative artificial intelligence in the practice and dissemination of Cornell’s academic research.
A new study found that patients with non-small cell lung cancer treated with a combination of low-dose radiation and immunotherapy had higher progression-free survival compared to patients who received immunotherapy alone.
In her annual Address to Staff on Jan. 11 – Ezra Cornell’s 216th birthday – President Martha E. Pollack highlighted achievements that are helping to sustain and re-imagine the university’s founding “… any person … any study” vision.
Researchers at Weill Cornell Medicine have catalogued the cellular response to stroke in a preclinical model, identifying the immune cells involved and the roles they may play in the days and weeks following a stroke.
Weill Cornell Medicine researchers received a $2.4 million grant from the U.S. Department of Defense Breast Cancer Research Program to evaluate a test that uses an artificial intelligence algorithm to determine whether a patient is positive for cancer.
Weill Cornell Medicine researchers and the TB Drug Accelerator have received two grants totaling $6.8 million from the Bill & Melinda Gates Foundation to study tuberculosis drug development.
